Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dana-Farber Cancer Institute, Boston, U.S.
New data from Dana-Farber Cancer Institute, Department of Medical Oncology illuminate research in thyroid cancer therapy
November 7th, 2006
Fresh data on thyroid cancer are presented in the report "Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. The ubiquitin-proteasome pathway is a major pathway for degradation of intracellular proteins. Proteasome inhibitors constitute a novel class of antitumor agents with preclinical and clinical evidence of activity against hematological malignancies and solid tumors," scientists in the United States report. "The proteasome inhibitor bortezomib (PS-341, Velcade) has been approved by the Food and Drug Administration for the treatment of multiple myeloma and is being studied intensely in several other...
Source: Drug Law Weekly (2006-11-07)
|
